Rubius therapeutics, inc. (RUBY)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-179,363

-163,458

-146,169

-125,516

-107,365

-89,195

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

40,281

41,271

39,566

39,095

34,393

27,528

0

0

0

Depreciation and amortization expense

4,123

2,995

2,678

2,207

1,697

1,263

0

0

0

Change in fair value of preferred stock warrant liability

-

-

-

-

-

2,187

0

0

0

Accretion of discount on investments

1,860

2,320

2,070

1,424

769

329

0

0

0

Non-cash interest expense

355

289

261

179

94

86

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-874

-2,655

8,374

9,914

6,204

9,037

0

0

0

Operating lease, right-of-use-asset

-6,061

-4,991

0

0

0

-

-

-

-

Accounts payable

834

-1,037

5,720

-2,836

3,520

4,938

0

0

0

Accrued expenses and other current liabilities

5,036

6,503

5,560

5,485

1,614

4,307

0

0

0

Deferred rent

-

-

-

-

-

-15

0

0

0

Operating lease liabilities

-4,265

-2,670

0

0

0

-

-

-

-

Net cash used in operating activities

-127,587

-110,444

-101,152

-90,265

-70,324

-58,341

0

0

0

Cash flows from investing activities:
Purchases of property, plant and equipment

39,344

40,657

30,662

30,909

18,286

14,952

0

0

0

Purchases of investments

211,151

319,133

332,834

259,446

222,807

160,972

0

0

0

Sales and maturities of investments

303,000

227,155

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

52,505

-132,635

-189,396

-185,606

-147,653

-111,639

0

0

0

Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

100,986

0

0

0

Proceeds from issuance of common stock upon exercise of stock options

2,100

2,413

1,889

1,417

859

64

0

0

0

Net cash provided by financing activities

26,978

27,291

45,884

300,666

274,638

374,829

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-48,104

-215,788

-244,664

24,795

56,661

204,849

0

0

0

Supplemental cash flow information:
Cash paid for interest, net of interest capitalized

3,520

2,961

0

0

0

-

-

-

0

Cash paid for leases

7,345

5,375

0

0

0

-

-

-

-

Supplemental disclosure of non-cash investing and financing information:
Lease assets obtained in exchange for new operating lease liabilities

-

49,799

0

0

0

-

-

-

-

Lease asset derecognized upon lease cancellation

0

-

-

-

-

-

-

-

-

Purchases of property, plant and equipment included in accounts payable or accrued expenses

-612

3,095

6,270

5,439

5,957

1,550

0

0

0

Amounts capitalized under build-to-suit lease transaction

-

-

-

-

-

-

0

0

0